5 Key Takeaways

• 1

  The FDA approved Agilent Technologies' companion diagnostic for identifying tumors expressing PD-L1 in gastric and esophageal cancers.

• 2

  The approval is for patients with esophageal squamous cell carcinoma, gastric tumors, gastroesophageal junction tumors, and esophageal adenocarcinoma.

• 3

  The PD-L1 IHC 28-8 pharmDx assay is a diagnostic aid for detecting PD-L1 expression with a Combined Positive Score of 1 or greater.

• 4

  Esophageal cancer is the 11th most common cancer globally, with over 510,000 new cases and 445,000 deaths annually.

• 5

  Gastric cancer ranks fifth in global incidence, with approximately 968,000 new cases and 660,000 deaths each year.